A detailed history of Park Avenue Securities LLC transactions in Argenx Se stock. As of the latest transaction made, Park Avenue Securities LLC holds 1,211 shares of ARGX stock, worth $760,895. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,211
Previous 1,324 8.53%
Holding current value
$760,895
Previous $569,000 15.29%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$434.22 - $551.9 $49,066 - $62,364
-113 Reduced 8.53%
1,211 $656,000
Q2 2024

Jul 09, 2024

BUY
$356.01 - $451.55 $31,684 - $40,187
89 Added 7.21%
1,324 $569,000
Q1 2024

Apr 10, 2024

BUY
$356.95 - $413.29 $75,673 - $87,617
212 Added 20.72%
1,235 $486,000
Q4 2023

Jan 10, 2024

BUY
$338.91 - $506.01 $56,936 - $85,009
168 Added 19.65%
1,023 $389,000
Q3 2023

Oct 26, 2023

BUY
$369.35 - $548.43 $315,794 - $468,907
855 New
855 $420,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Park Avenue Securities LLC Portfolio

Follow Park Avenue Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Park Avenue Securities LLC with notifications on news.